Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 191

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly

Open access
Colao, Annamaria, Attanasio, Roberto, Pivonello, Rosario, Cappabianca, Paolo, Cavallo, Luigi M., Lasio, Giovanni, Lodrini, Alessandro, Lombardi, Gaetano, Cozzi, Renato·2006·The Journal of Clinical Endocrinology & Metabolism
DOI 10.1210/jc.2005-1208
Open this paper in CoChat — free account

Abstract

Context: Surgery is a cornerstone in the treatment of acromegaly, but its efficacy in large, invasive tumors is scant. Objective: The objective of this study was to investigate whether partial surgical removal of GH-secreting pituitary tumors enhances the response rate to somatostatin analogs (SSA; sc octreotide, slow-release octreotide, and lanreotide). Design: This was a multicenter, open, retrospective study. Setting: The study was performed at university hospitals. Subjects and Methods: Eighty-six patients (42 women and 44 men; age, 42 ± 14 yr) with acromegaly were studied. Interventions: Patients underwent two courses of octreotide, lanreotide, or slow-release octreotide treatments before and after surgery of at least 6 months. Main Outcome Measure: The main outcome measure was normal IGF-I levels for age. Results: Presurgical SSA treatment significantly decreased GH and IGF-I levels in all patients. GH levels were less than 2.5 μg/liter in 12 patients (14%); IGF-I levels normalized in nine (10%). After surgery, GH and IGF-I levels further decreased in all patients; tumor removal was greater than 75% in 50 (58%), 50.1–75% in 21 (24%), 25.1–50% in 10 (12%), and less than 25% in five patients (6%). Preoperatively, pituitary function was impaired in 12 patients (14%). Postsurgical SSA treatment lowered GH levels to less than 2.5 μg/liter in 49 (56%) and normalized IGF-I levels in 48 patients (55%). The success rate was significantly increased compared with that before surgery (P < 0.0001). GH (r = −0.48; P < 0.0001) and IGF-I levels (r = −0.38; P = 0.0003) after postsurgery SSA treatment correlated with the amount of tumor surgically removed. After surgery, pituitary function was impaired in 28 patients (32.6%) and was improved in 12 patients (13.9%). The cumulative prevalence of pituitary deficiency did not change during the study (normal function from 40 to 42%; deficiency from 60 to 58%). Conclusions: Surgical tumor removal (>75%) enhances the response to SSAs without impairing pituitary function. Our data indicate that surgical debulking has a significant place in the treatment algorithm of acromegaly.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2005-1208

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Research works printed but not linked: 32

  1. Orme, 1998, Mortality and cancer incidence in acromegaly: a retrospective cohort study., J Clin Endocrinol Metab, 83, 2730
  2. Holdaway, 2004, Factors influencing mortality in acromegaly., J Clin Endocrinol Metab, 89, 667, 10.1210/jc.2003-031199 · DOI · Paper page
  3. Ayuk, 2004, Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly., J Clin Endocrinol Metab, 89, 1613, 10.1210/jc.2003-031584 · DOI · Paper page
  4. Kauppinen-Makelin, 2005, A nationwide survey of mortality in acromegaly., J Clin Endocrinol Metab, 90, 4081, 10.1210/jc.2004-1381 · DOI · Paper page
  5. Swearingen, 1998, Long-term mortality after transsphenoidal surgery and adjunctive therapy for acromegaly., J Clin Endocrinol Metab, 83, 3419
  6. Beauregard, 2003, Long-term outcome and mortality after transsphenoidal adenomectomy for acromegaly., Clin Endocrinol (Oxf), 58, 86, 10.1046/j.1365-2265.2003.01679.x · DOI · Paper page
  7. Colao, 2004, Systemic complications of acromegaly: epidemiology, pathogenesis and management., Endocr Rev, 25, 102, 10.1210/er.2002-0022 · DOI · Paper page
  8. Melmed, 2002, Guidelines for acromegaly management., J Clin Endocrinol Metab, 87, 4054, 10.1210/jc.2002-011841 · DOI · Paper page
  9. Newman, 1998, Octreotide as primary therapy for acromegaly., J Clin Endocrinol Metab, 83, 3034
  10. Sheppard, 2003, Primary medical therapy for acromegaly., Clin Endocrinol (Oxf), 58, 387, 10.1046/j.1365-2265.2003.01734.x · DOI
  11. Colao, 1997, Effect of octreotide pretreatment on surgical outcome in acromegaly., J Clin Endocrinol Metab, 82, 3308, 10.1210/jcem.82.10.4283 · doi:10.1210/jcem.82.10.4283 · Paper page
  12. Ben-Shlomo, 2003, The role of pharmacotherapy in perioperative management of patients with acromegaly., J Clin Endocrinol Metab, 88, 963, 10.1210/jc.2002-020072 · doi:10.1210/jc.2002-020072
  13. Bevan, 2005, The antitumoral effects of somatostatin analog therapy in acromegaly., J Clin Endocrinol Metab, 90, 1856, 10.1210/jc.2004-1093 · doi:10.1210/jc.2004-1093
  14. Melmed, 2005, A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly., J Clin Endocrinol Metab, 90, 4405, 10.1210/jc.2004-2466 · DOI · Paper page
  15. Colao, 2001, Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly., J Clin Endocrinol Metab, 86, 2779
  16. Freda, 2002, Somatostatin analogs in acromegaly., J Clin Endocrinol Metab, 87, 3013, 10.1210/jcem.87.7.8665 · doi:10.1210/jcem.87.7.8665 · Paper page
  17. Cozzi, 2003, Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results?, J Clin Endocrinol Metab, 88, 3090, 10.1210/jc.2003-030110 · DOI · Paper page
  18. Attanasio, 2003, Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly., J Clin Endocrinol Metab, 88, 5258, 10.1210/jc.2003-030266 · doi:10.1210/jc.2003-030266
  19. Petrossians, 2005, Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs., Eur J Endocrinol, 152, 1, 10.1530/eje.1.01824 · doi:10.1530/eje.1.01824
  20. Lissett, 1998, The outcome of surgery for acromegaly: the need for a specialist pituitary surgeon for all types of growth hormone secreting adenomas., Clin Endocrinol (Oxf), 49, 653, 10.1046/j.1365-2265.1998.00581.x · DOI
  21. Giustina, 2000, Criteria for cure of acromegaly: a consensus statement., J Clin Endocrinol Metab, 85, 526
  22. Colao, 1998, Growth hormone and prolactin excess., Lancet, 352, 1455, 10.1016/S0140-6736(98)03356-X · DOI · Paper page
  23. Stewart, 1999, Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR)., Clin Endocrinol (Oxf), 50, 295, 10.1046/j.1365-2265.1999.00660.x · DOI
  24. Colao, 1996, Prediction of efficacy of octreotide therapy in patients with acromegaly., J Clin Endocrinol Metab, 81, 2356
  25. Nomikos, 2005, The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical ‘cure.’, Eur J Endocrinol, 152, 379, 10.1530/eje.1.01863 · DOI · Paper page
  26. Freda, 1998, Long-term endocrinological follow-up evaluation in 115 patients who underwent transsphenoidal surgery for acromegaly., J Neurosurg, 89, 353, 10.3171/jns.1998.89.3.0353 · DOI · Paper page
  27. De, 2003, Transsphenoidal surgery for acromegaly in Wales: results based on stringent criteria of remission., J Clin Endocrinol Metab, 88, 3567, 10.1210/jc.2002-021822 · DOI
  28. Kreutzer, 2001, Surgical management of GH-secreting pituitary adenomas: an outcome study using modern remission criteria., J Clin Endocrinol Metab, 86, 4072, 10.1210/jcem.86.9.7819 · doi:10.1210/jcem.86.9.7819 · Paper page
  29. Sheaves, 1996, Outcome of transsphenoidal surgery for acromegaly using strict criteria for surgical cure., Clin Endocrinol (Oxf), 45, 407, 10.1046/j.1365-2265.1996.8370847.x · DOI · Paper page
  30. Chanson, 2000, Efficacy and tolerability of the long-acting somatostatin analog lanreotide in acromegaly. A 12-month multicenter study of 58 acromegalic patients. French Multicenter Study Group on Lanreotide in Acromegaly., Pituitary, 2, 269, 10.1023/A:1009961116472 · doi:10.1023/a:1009961116472
  31. Didoni, 2004, Cost-of-illness study in acromegalic patients in Italy., J Endocrinol Invest, 27, 1034, 10.1007/BF03345306 · DOI
  32. Attanasio, 2003, γ-Knife radiosurgery in acromegaly: a 4-year-follow-up study., J Clin Endocrinol Metab, 88, 3105, 10.1210/jc.2002-021663 · DOI · Paper page

Cited by

See all 191

Metadata

Authors
Colao, A., Attanasio, R., Pivonello, R., Cappabianca, P., Cavallo, L. M., Lasio, G., Lodrini, A., Lombardi, G., & Cozzi, R.
Venue
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Published
2006-01-01
Volume
91
Issue
1
Pages
85-92
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
DOI
10.1210/jc.2005-1208
OpenAlex
W2091704139
Cited by
191
References
3
FWCI
11.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly. https://app.cochat.ai/papers/10.1210/jc.2005-1208
The paper
Colao, A., Attanasio, R., Pivonello, R., Cappabianca, P., Cavallo, L. M., Lasio, G., Lodrini, A., Lombardi, G., & Cozzi, R. (2006). Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2005-1208

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.